NLM Digital Collections

Search

Start Over Collections Health Policy and Services Research ✖Remove constraint Collections: Health Policy and Services Research Subjects United States ✖Remove constraint Subjects: United States Recently Added Within 6 Months ✖Remove constraint Recently Added: Within 6 Months Dates by Range 2000 and later ✖Remove constraint Dates by Range: 2000 and later

313. VA health care: Office of the Medical Inspector should strengthen oversight of recommendations and assess performance : report to congressional requesters

Publication:
Washington, DC : United States Government Accountability Office, July 2023
Subject(s):
Government Regulation
Legislation, Medical
Outcome and Process Assessment, Health Care -- legislation & jurisprudence
United States
United States. Veterans Health Administration. Office of the Medical Inspector

314. Veterans health care: VA has taken steps to improve its appointment scheduling process, but additional actions are needed : testimony before the Special Committee on Aging, U.S. Senate

Publication:
Washington, DC : United States Government Accountability Office, May 17, 2023
Subject(s):
Appointments and Schedules
Government Regulation
Legislation, Medical
Veterans Health Services -- organization & administration
United States
United States. Department of Veterans Affairs

315. Voluntary consensus standards recognition program for regenerative medicine therapies: guidance for industry

Publication:
Silver Spring, MD : Center for Biologics Evaluation and Research, October 2023
Subject(s):
Drug Industry
Government Regulation
Reference Standards
Regenerative Medicine -- legislation & jurisprudence
Regenerative Medicine -- standards
Voluntary Programs
United States
Center for Biologics Evaluation and Research (U.S.)

320. Wholesale distributor verification requirement for saleable returned drug product and dispenser verification requirements when investigating a suspect or illegitimate product: compliance policies : guidance for industry

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, August 2023
Subject(s):
Counterfeit Drugs
Drug Industry
Drug and Narcotic Control
Fraud
Government Regulation
Substandard Drugs
United States
United States.